Get the Stockscreener App
1.23
0.82%
0.01
Pre-market:
1.27
0.04
+3.25%
Coherus Oncology Inc stock is traded at $1.23, with a volume of 712.34K.
It is up +0.82% in the last 24 hours and down -20.65% over the past month.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
See More
Previous Close:
$1.22
Open:
$1.22
24h Volume:
712.34K
Relative Volume:
0.58
Market Cap:
$148.67M
Revenue:
$257.24M
Net Income/Loss:
$-237.89M
P/E Ratio:
-0.4731
EPS:
-2.6
Net Cash Flow:
$-175.17M
1W Performance:
-6.11%
1M Performance:
-20.65%
6M Performance:
+54.33%
1Y Performance:
-28.07%
1-Day Range:
$1.20
$1.25
1-Week Range:
$1.15
$1.385
52-Week Range:
$0.71
$1.89
Coherus Oncology Inc Stock (CHRS) Company Profile
Name
Coherus Oncology Inc
Sector
Industry
Phone
(650) 649-3530
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.23 | 147.46M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Upgrade | Maxim Group | Hold → Buy |
| Aug-16-24 | Downgrade | UBS | Buy → Neutral |
| Nov-17-23 | Initiated | Robert W. Baird | Outperform |
| Nov-08-23 | Downgrade | Maxim Group | Buy → Hold |
| Jul-24-23 | Initiated | Citigroup | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Mar-28-23 | Upgrade | UBS | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Neutral |
| Mar-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-16-20 | Initiated | BofA Securities | Neutral |
| Apr-17-20 | Initiated | SunTrust | Buy |
| Aug-13-19 | Initiated | Mizuho | Buy |
| Aug-02-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-02-19 | Reiterated | Maxim Group | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-07-19 | Initiated | H.C. Wainwright | Buy |
| Aug-28-18 | Initiated | H.C. Wainwright | Buy |
| Mar-09-18 | Reiterated | Maxim Group | Buy |
| Aug-08-17 | Reiterated | JP Morgan | Overweight |
| Jun-13-17 | Reiterated | Maxim Group | Buy |
| May-05-17 | Initiated | BMO Capital Markets | Outperform |
| Oct-19-16 | Initiated | Robert W. Baird | Outperform |
| Sep-07-16 | Initiated | Maxim Group | Buy |
| Jul-27-16 | Initiated | Citigroup | Buy |
| Jan-20-16 | Initiated | Credit Suisse | Outperform |
View All
Coherus Oncology Inc Stock (CHRS) Latest News
Why Coherus Oncology Inc. (8C5) stock stays on top picks2025 Top Gainers & Expert Curated Trade Setups - Newser
Why global investors buy Coherus Oncology Inc. (8C5) stockJuly 2025 Earnings & Expert Verified Movement Alerts - Newser
Does Coherus Oncology Inc. (8C5) stock trade below intrinsic valueMarket Volume Summary & Community Consensus Stock Picks - Newser
Why Coherus Oncology Inc. (8C5) stock could rally strongly2025 Trading Volume Trends & Free Safe Entry Trade Signal Reports - Newser
Can Coherus Oncology Inc. (8C5) stock sustain free cash flow2025 Macro Impact & AI Enhanced Trading Alerts - Newser
Can Coherus Oncology Inc. (8C5) stock hold up in economic slowdownTrade Risk Assessment & Fast Gain Stock Tips - Newser
How strong is Coherus Oncology Inc. (8C5) stock earnings growthAnalyst Downgrade & Safe Entry Zone Identification - Newser
Coherus Oncology (CHRS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Can Coherus Oncology Inc. (8C5) stock survive global slowdown2025 Earnings Surprises & Safe Swing Trade Setups - BỘ NỘI VỤ
Is Coherus Oncology Inc 8C5 a good long term investmentEconomic Impact on Stocks & Build Wealth Brick by Brick With Us - earlytimes.in
What analysts say about Coherus Oncology Inc 8C5 stockGap Up/Gap Down Analysis & Outstanding Profit Strategies - earlytimes.in
Will Coherus Oncology Inc. (8C5) stock top growth indexesJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com
Will Coherus Oncology Inc. (8C5) stock outperform value peersPortfolio Update Summary & High Conviction Buy Zone Alerts - newser.com
Can Coherus Oncology Inc. (8C5) stock attract analyst upgradesJuly 2025 Selloffs & Risk Managed Investment Signals - newser.com
Will Coherus Oncology Inc. (8C5) stock benefit from infrastructure billOil Prices & Technical Confirmation Trade Alerts - newser.com
How Coherus Oncology Inc. (8C5) stock reacts to Fed tighteningWeekly Trade Analysis & Consistent Growth Stock Picks - newser.com
Is Coherus Oncology Inc. (8C5) stock included in top ETFs2025 Top Decliners & AI Forecasted Entry and Exit Points - newser.com
Can Coherus Oncology Inc. (8C5) stock retain market dominanceWeekly Risk Summary & AI Enhanced Trading Signals - newser.com
Coherus BioSciences at Jefferies: Strategic Oncology Focus By Investing.com - Investing.com Canada
Coherus BioSciences at Jefferies: Strategic Oncology Focus - Investing.com
CHRS: Innovative oncology pipeline advances with strong data, global rights, and strategic partnerships - TradingView
Coherus Oncology Inc Stock (CHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):